Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (NYSE:AZN) received a positive boost after their combination of Amgen’s Imdelltra and AstraZeneca’s Imfinzi significantly improved overall survival in a late-stage trial involving patients with extensive-stage small-cell lung cancer. The combination was tested as a maintenance treatment against Imfinzi alone in patients whose disease had not progressed after initial therapy.
Beyond overall survival, the combination also improved progression-free survival and response rates, with no new safety concerns identified. For Amgen, the result is particularly relevant because Imdelltra generated $513 million in sales last year and could now have a broader role in the treatment of small-cell lung cancer.
A Potential Boost to Oncology Revenues
The trial strengthens the commercial outlook for Imdelltra and gives Amgen Inc. another opportunity to expand one of its newer oncology assets beyond its existing use. Imdelltra already has full U.S. approval for extensive-stage small-cell lung cancer, and demonstrating an overall-survival benefit when combined with Imfinzi could make the drug more important earlier in the treatment journey. Since cancer therapies already account for roughly 23% of Amgen’s sales, a successful expansion of Imdelltra could further diversify the company’s revenue base and reduce reliance on its older products. The fact that the combination improved not only overall survival but also progression-free survival and response rates makes the result more commercially meaningful than a single positive endpoint. Amgen’s broader business is also entering this result from a position of strength, with second-quarter 2026 revenue up 10% and sales of key growth products increasing substantially.
The result provides another positive data point for AstraZeneca PLC’s large oncology franchise and potentially extends the commercial opportunity for Imfinzi, one of its established cancer drugs. Because Imfinzi is already approved across several cancer indications, demonstrating that it can work effectively in combination with Imdelltra could reinforce its position in small-cell lung cancer and support additional revenue from combination-based treatment. More importantly, the positive survival result comes at a useful time for AstraZeneca, whose investor confidence has recently been pressured by clinical setbacks, including the discontinuation of its volrustomig lung-cancer trial. The success therefore gives investors evidence that AstraZeneca’s oncology pipeline still has meaningful depth, while the company continues targeting $80 billion in annual revenue by 2030.
Promising Data, But Bigger Challenges Remain
For Amgen Inc., the biggest limitation is that the positive trial result does not automatically translate into a blockbuster revenue opportunity for Imdelltra. The drug generated $513 million in sales last year, meaning the company would need substantial uptake in the maintenance setting to make the trial financially material relative to Amgen’s overall scale. Competition in oncology is also intense, and physicians may weigh the incremental survival benefit, treatment complexity, safety, and reimbursement before broadly adopting the combination. In addition, Amgen’s investment case is much broader than Imdelltra, so even a strong commercial launch may have only a modest impact on the company’s total earnings unless the drug becomes a much larger contributor.
For AstraZeneca PLC, the result is encouraging but probably does not erase the broader pipeline concerns weighing on the stock. The company has suffered several recent setbacks, including the failure of Wainua in a late-stage heart-disease trial and the discontinuation of its volrustomig lung-cancer study. That means investors are likely to continue judging AstraZeneca on a much wider set of pipeline outcomes rather than one successful combination study. The positive Imfinzi data also represents an expansion of an existing franchise rather than the arrival of an entirely new blockbuster, so the incremental financial impact could be less dramatic than the headline clinical success suggests. Recent market commentary has nevertheless argued that AstraZeneca’s shares have been overly punished and that successful pipeline developments could support a recovery.
Conclusion
Overall, the trial is clearly positive for both stocks, but the impact is more about strengthening their long-term oncology franchises than immediately transforming their earnings outlook. Amgen Inc. gets a meaningful validation of Imdelltra and a potential path to expanding the drug’s commercial reach, while AstraZeneca PLC gets another piece of evidence supporting its broader oncology strategy and Imfinzi franchise.
However, investors should avoid treating the result as a standalone game changer: Amgen still needs to turn the clinical success into substantial sales, while AstraZeneca must overcome several recent pipeline disappointments. On balance, the news is more constructive for AstraZeneca’s sentiment and pipeline credibility, while providing Amgen with a potentially valuable additional growth opportunity through Imdelltra.
READ NEXT: Bristol Myers’ Cancer Therapy Win Strengthens its Oncology Pipeline and Google and Accenture Team Up to Accelerate Enterprise AI Adoption
This article is originally published at Insider Monkey.
Hedge Fund Resource Center